RxDoctor Payments Data

Lisa Wang, MD

Psychiatry · Richmond, CANPI 1326113671

Payments from drug & device makers

$974in general payments, 2019–2025

Across 26 payments — averaging $37.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$196
  • Amgen$188
  • Johnson & Johnson$176
  • Neurocrine Biosciences, Inc.$145
  • Otsuka America Pharmaceutical, Inc.$139
  • Alkermes, Inc.$44
  • plus $86 from 3 others

What the payments were for

  • Food & beverage$75696%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$974 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$16,938
Medicare patients
49
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate94$248,757
IngrezzaValbenazine Tosylate12$93,083
RexultiBrexpiprazole40$59,092
VraylarCariprazine Hcl29$39,353
Abilify MaintenaAripiprazole14$32,046
Risperdal ConstaRisperidone Microspheres25$22,896
Clozapine107$11,186
Aripiprazole85$9,153
TrintellixVortioxetine Hydrobromide16$8,837
Haloperidol Decanoate119$8,198
Lurasidone Hcl30$6,171
Quetiapine Fumarate167$5,587
Olanzapine268$5,319
LoxapineLoxapine Succinate47$2,728
Fluphenazine Hcl38$2,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$176$271,653119 claims
Neurocrine Biosciences, Inc.Ingrezza$145$93,08312 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$139$91,13854 claims
AbbVieVraylar$196$39,35329 claims
Teva Pharmaceuticals USA, Inc.Loxapine$37$2,72847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Richmond

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →